379 Immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma (STS) treated with neoadjuvant immune checkpoint blockade (ICB)

B. Ashleigh Guadagnolo ,Ignacio I. Wistuba ,Emily Z. Keung ,Shadarra Crosby,Keila E. Torres ,Christopher P. Scally ,Valerae O. Lewis ,Cibelle Freitas Pinto Lima ,Elise F. Nassif ,Neeta Somaiah,Andrew J. Bishop ,Heather Lin,Jennifer A. Wargo ,Alexander J. Lazar ,Edwin R. Parra ,Khalida Wani,Barry W. Feig ,Wei‐Lien Wang ,Grace Mathew,Davis R. Ingram ,Kelly K. Hunt ,Christina L. Roland ,Ahmed Al Rawi

doi:10.1136/jitc-2021-sitc2021.379

379 Immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma (STS) treated with neoadjuvant immune checkpoint blockade (ICB)

B. Ashleigh Guadagnolo , Ignacio I. Wistuba + Show 21 more

Open Access

https://doi.org/10.1136/jitc-2021-sitc2021.379

Copy DOI

Journal: Journal for ImmunoTherapy of Cancer	Publication Date: Nov 1, 2021
Citations: 2	License type: cc-by-nc-nd

Affiliation: The University of Texas MD Anderson Cancer Center

#Dedifferentiated Liposarcoma #Undifferentiated Pleomorphic Sarcoma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundRecurrences are common after surgery for localized STS.1 2 ICB has shown activity in metastatic undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS)3 with intratumoral B-cells associated with improved outcomes.4...

Full Text